Drug Trial Radar · NCT01231607
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
Last checked: Nov 19, 2026Latest source record: Aug 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
917
Actual
Start
Oct 28, 2010
Primary completion
Feb 1, 2012
Study completion Feb 28, 2012
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.
Conditions
- Androgenetic Alopecia
Interventions
1mg Finasteride activeDrug
1mg finasteride active, by mouth once daily
0.02mg dutasterideDrug
0.02mg dutasteride active, by mouth once daily
0.1mg dutasterideDrug
0.1mg dutasteride active, by mouth once daily
0.5mg dutasterideDrug
0.5mg dutasteride active, by mouth once daily
Finasteride placeboDrug
finasteride placebo, by mouth once daily
Dutasteride placeboDrug
dutasteride placebo, by mouth once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)Time frame: Baseline and Week 24
Locations
39 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
CABA, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
La Boca, Buenos Aires, Argentina
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Viña del Mar, Valparaiso, Chile
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Zapopan, Jalisco, Jalisco, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Mazatlan, Sinaloa, Sinaloa, Mexico
GSK Investigational Site
Naucalpan, State of Mexico, Mexico
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima Cercado, Peru
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Makati City, Philippines
GSK Investigational Site
Manila, Philippines
GSK Investigational Site
Quezon City, Philippines
GSK Investigational Site
Quezon City, Philippines
GSK Investigational Site
Tanauan City, Batangas, Philippines
GSK Investigational Site
Moscow, Russia
GSK Investigational Site
Nizhny Novgorod, Russia
GSK Investigational Site
Ryazan, Russia
GSK Investigational Site
Saint Petersburg, Russia
GSK Investigational Site
St'Petersburg, Russia
GSK Investigational Site
Tainan, Taiwan
GSK Investigational Site
Taipei, Taiwan
GSK Investigational Site
Taipei, Taiwan
GSK Investigational Site
Taipei, Taiwan
GSK Investigational Site
Bangkoknoi Bangkok, Thailand
GSK Investigational Site
Chiang Mai, Thailand
GSK Investigational Site
Patumwan Bangkok, Thailand
GSK Investigational Site
Rajthevee Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.